Watch for Telix shareholder vote in November 2026 and regulatory milestones for ITM-11 (FDA approval milestones up to $250M). The deal significantly de-risks Telix's therapeutic pipeline with a Phase 3-ready asset and secures critical isotope supply. Monitor integration execution and any competitive responses in the radiopharmaceutical space.
Price Chart
Executive Summary
Telix announces a transformational merger with ITM Isotope Technologies Munich SE for $1.65B upfront (cash-free/debt-free), plus up to $700M in contingent milestones. The deal combines Telix's commercial theranostics platform with ITM's leading radioisotope production and late-stage pipeline (ITM-11 for GEP-NETs), creating a vertically integrated radiopharmaceutical leader. Pro forma 2026 revenue is expected to exceed $1.3B, and the transaction is expected to close by end of FY 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Upfront consideration of $1.65 billion on a cash-free/debt-free basis; after adjustments, ITM shareholders to receive ~$1.25 billion in Telix shares at $11.841 per share (105.8M shares).
- Additional contingent consideration of up to $700 million tied to FDA approvals and commercial sales milestones for ITM-11.
- ITM generated $273 million in annual revenue in 2025 with a 40% CAGR from 2021-2025; its radioisotope manufacturing business is profitable and cash-flow positive.
- Combined pro forma 2026 revenue and income expected to exceed $1.3 billion.
- ITM-11 (177Lu-edotreotide) has completed a successful Phase 3 trial (COMPETE) for GEP-NETs; interim analysis for second Phase 3 (COMPOSE) expected H1 2027.
- Telix shareholders will own ~76.3% and ITM shareholders ~23.7% of the combined company.
- Transaction expected to close by end of FY 2026, subject to Telix shareholder approval (EGM in November 2026) and regulatory approvals.
Financial Impact
$1.65B upfront plus up to $700M contingent; combined pro forma revenue >$1.3B in 2026
Risk Factors
- Shareholder approval required; any delay or rejection could scuttle the deal.
- Integration risk combining two organizations across multiple geographies and manufacturing sites.
- Contingent milestones depend on FDA approvals and commercial uptake of ITM-11, which may not materialize as expected.
- Dilution from 105.8M new shares (~23.7% of pro forma equity) may pressure near-term stock price.
- Assumption of $302M net debt adds leverage to Telix's balance sheet.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365113 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.05 (−9.82%) |
Oct 20, 2026 6d ago | Press Release | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.05 (−9.82%) |
Sep 29, 2026 27d ago | 6-K | $10.97 $10.72 | ▼ −2.28% | ▼ −2.46% | $9.05 (−17.55%) |
Sep 21, 2026 5w ago | 6-K | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.05 (−20.03%) |
Sep 20, 2026 5w ago | Press Release | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.05 (−20.03%) |
Sep 14, 2026 6w ago | 6-K | $12.83 $11.83 | ▼ −7.79% | ▼ −7.35% | $9.05 (−29.50%) |
Sep 14, 2026 6w ago | Press Release | $11.78 $12.83 | ▲ +8.91% | ▲ +9.37% | $9.05 (−23.22%) |
Sep 1, 2026 7w ago | 6-K | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.05 (−21.00%) |
Sep 1, 2026 7w ago | Press Release | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.05 (−21.00%) |
Aug 19, 2026 9w ago | 6-K | $12.42 $11.33 | ▼ −8.78% | ▼ −9.19% | $9.05 (−27.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers